Drug Discovery World

AUGUST 9, 2022

Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. . This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. In the same study, those with T790M loss had a shorter treatment duration (6.1 months vs. 15.2

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

APRIL 8, 2024

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

OCTOBER 30, 2023

GeNeuro and Verily will work together to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. The post Partners take a personalised approach to long Covid appeared first on Drug Discovery World (DDW).

In-Vitro 52

In-Vitro Protein Medicine Drugs 52

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. In addition, they discovered that cladribine, a clinical drug, activates DGKB and inhibits DGAT1. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 2, 2023

Karikó and Weissman noticed that dendritic cells recognise in vitro transcribed mRNA as a foreign substance, which leads to their activation and the release of inflammatory signalling molecules. The effect was due to the reduced activation of an enzyme that regulates protein production. Image credit: Ill.

In-Vitro 64

In-Vitro Protein Vaccination Vaccine 64

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Drug Discovery World

OCTOBER 21, 2022

Proteomics, the study of proteins in the human body, has emerged as a promising field in medicine, particularly for its potential to identify subtypes of cancers and match patients with the most appropriate treatment strategy. The post South Korean proteomics company Bertis expands to the US appeared first on Drug Discovery World (DDW).

In-Vitro 52

In-Vitro Protein Medicine Research 52

Drug Discovery World

AUGUST 3, 2023

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Although target directed drug discovery is the most common approach, it is slow and expensive and has high attrition rates. Phenotyping, in contrast, can produce a hit/lead without a target.

Research 52

Research Drugs In-Vitro Insulin 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

Drug Discovery World

JANUARY 25, 2024

The research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Drug Discovery 2022: The numbers . Drug Discovery 2022: The numbers . Of those delegates, 75% work in drug discovery.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

JUNE 27, 2023

The post IRBM and Merck extend peptide therapeutics collaboration appeared first on Drug Discovery World (DDW). Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

JANUARY 23, 2023

Ubiquigent is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a (de)ubiquitylation (DUB) implicated in neurodegenerative, renal, and cardiovascular diseases. Overseen by Professor Helen Walden, UoG, and Dr Mehmet Gundogdu, Principal Scientist at Ubiquigent, the project aims to combine biochemistry, (..)

In-Vitro 52

In-Vitro Protein Regulation Scientist 52

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. 3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and sustainability.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

Pharmaceutical Technology

AUGUST 11, 2022

Further in vitro studies demonstrated that the most common variant that caused a loss in INHBE function was linked to a significant reduction in the secretion of the Activin E protein.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Like all drugs, biologics are regulated by the FDA.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

XTalks

APRIL 18, 2024

Roche has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Elecsys pTau217 early Alzheimer’s blood test. The Elecsys pTau217 assay is designed to detect amyloid pathology, a hallmark of Alzheimer’s disease, by measuring phosphorylated tau protein in human plasma.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Drug Discovery World

MARCH 23, 2023

Consistent with first-generation PI3Kdinhibitors, roginolisib inhibits the in vitro growth of lymphoma cells. In CT26 colorectal and LLC lung cancer models, roginolisib sensitised the tumours to anti-PD-1 (Programmed cell death protein 1) treatment, with similar activity in the Pan-02 pancreatic and A20 lymphoma syngeneic mouse models.

Research 98

Research In-Vitro Clinical Research Genome 98

Drug Discovery World

JANUARY 17, 2024

The research team conducted experiments involving ‘Mitofusin2’ (MFN2), a protein that is necessary for mitochondria tethering in MAMs. The results were consistent with the in vitro experiments. Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

Drug Discovery World

DECEMBER 13, 2022

The genetic anomaly blocks the chemical glycosylation of a biologically important protein. Using an experimental technique called exon skipping by antisense oligonucleotides, the team corrected a mistake in the FKTN gene that blocks the chemical glycosylation of a biologically important protein. . Modifying RNA function.

RNA 52

RNA Genetics Gene In-Vitro 52

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.

Protein 52

Protein Production Antibody In-Vitro 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

The Pharma Data

MAY 31, 2022

Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Evrysdi is now approved in the US to treat SMA in children and adults of all ages.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

JUNE 30, 2023

Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers. Sample preparation contributes to the overall success of diagnostic testing by removing interfering substances such as cell debris, proteins, lipids or inhibitors.

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING. It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 AUTHORIZED USE.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ In vitro studies showed that when OYA1 is dosed with remdesivir both compounds are markedly more effective inhibiting Ebola virus replication and do so at much lower doses than is needed with either compound alone.

Clinical Trials 40

Clinical Trials Clinical Trials Drugs In-Vitro 40

XTalks

MARCH 6, 2024

Brain Awareness Week 2024 , taking place March 11 to 17 this year, is a global campaign that aims to demystify the complexities of the human brain and promote the significance of neuroscientific research. This relates to neurological conditions like dementia and Alzheimer’s disease, which account for up to 70 percent of dementia cases.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69